Spotlight On ATTR-CM
Welcome to Spotlight On ATTR-CM, your go-to source for the latest research, diagnostic advancements, and therapeutic strategies in transthyretin amyloid cardiomyopathy (ATTR-CM). Join leading cardiologists and researchers as they share their insights on this intricate condition to enhance patient care and outcomes.
76-81 of 81
ATTR-CM Epidemiology: Prevalence, Incidence, and Recognition Trends
Spotlight On ATTR-CMATTR-CM Epidemiology: Prevalence, Incidence, and Recognition Trends
Tafamidis in ATTR-CM: Established, Chronic, and Not Acute Rescue
Spotlight On ATTR-CMTafamidis in ATTR-CM: Established, Chronic, and Not Acute Rescue
Pathophysiology in ATTR-CM: Infiltration, Remodeling, and Stage-Dependent Effect
Spotlight On ATTR-CMPathophysiology in ATTR-CM: Infiltration, Remodeling, and Stage-Dependent Effect
How Multidisciplinary Care Supports Tafamidis in ATTR-CM
Spotlight On ATTR-CMHow Multidisciplinary Care Supports Tafamidis in ATTR-CM
Differential Diagnosis in ATTR-CM: 99mTc-PYP Scintigraphy and Diagnostic Workup
Spotlight On ATTR-CMDifferential Diagnosis in ATTR-CM: 99mTc-PYP Scintigraphy and Diagnostic Workup
Refractory Disease in ATTR-CM: Tafamidis and Treatment Decisions
Spotlight On ATTR-CMRefractory Disease in ATTR-CM: Tafamidis and Treatment Decisions
- advertisement
